If you’ve heard of GLP-1 drugs at all, it’s probably as the blockbuster medicines behind today’s biggest weight-loss and diabetes headlines—think Ozempic, Wegovy, Mounjaro, and the rest of the semaglutide and tirzepatide family. But a large new study suggests these medications may have a quieter, less visible superpower: helping people recover more safely after surgery. Researchers at McGovern Medical School at UTHealth Houston analyzed millions of patient records and found that people taking GLP-1 receptor agonists before an elective operation had lower odds of serious cardiovascular complications and postoperative infections than those not taking the drugs. The results, published in the medical journal Anesthesiology, caught even the study’s lead author by surprise. Dr. Josephine Tolan told Newsweek that she was struck by how consistent the benefit appeared, with GLP-1 use linked to an 11 percent drop in the odds of major cardiovascular events and an 8 percent drop in the odds of postoperative infections. That may not sound like a dramatic transformation for any one person, but across the millions of surgeries performed each year, those numbers could translate into thousands of avoided heart attacks, strokes, and infections. The real message, according to the researchers, is that these medications might be doing more than controlling appetite and blood sugar—they may also be calming the body’s inflammatory response, especially at a time when surgery puts the whole system under stress.
To understand how the study worked, it helps to picture the sheer scale of the data. The team turned to EPIC COSMOS, a massive electronic health record system that pulls together information from more than 1,700 hospitals and 40,000 clinics across the United States. From that database, they identified just over two million adults who had elective, non-cardiac surgeries lasting longer than an hour and requiring at least 24 hours in the hospital, with procedures taking place between January 2016 and December 2024. Among those patients, about 145,610 were already taking a GLP-1 medication at the time of their surgery. Because people who take these drugs can differ in important ways from people who don’t—they may have more obesity, diabetes, or other metabolic conditions—the researchers couldn’t simply compare the two groups directly. Instead, they used statistical matching techniques to create comparable groups, balancing factors like age, underlying health, and the type of surgery. Then they looked at two major sets of outcomes. The first was major adverse cardiovascular events, known in shorthand as MACE, which included heart attack, myocardial injury, stroke, and death from any cause. The second was postoperative infections, including surgical site infections, urinary tract infections, pneumonia, and sepsis. The results showed that major cardiovascular events occurred in 1 percent of GLP-1 users compared with 1.1 percent of non-users, while postoperative infections occurred in 4.9 percent of GLP-1 users versus 5.3 percent of non-users. Those absolute differences are small, but they are consistent enough to suggest something real is happening.
What could explain this protective effect? The researchers point to a few possibilities, and the most intriguing one is inflammation. GLP-1 medications were originally designed to help people with type 2 diabetes manage their blood sugar, and they do that by mimicking a natural hormone that stimulates insulin release and slows digestion. Over time, though, studies have shown that these drugs do much more than that. They have been linked to reduced risks of major cardiovascular events, improved kidney function, and even changes in the way the immune system behaves. In particular, GLP-1 receptor agonists appear to modulate inflammatory pathways throughout the body, lowering the production of pro-inflammatory molecules and making blood vessels less prone to injury. That matters enormously in the surgical setting, because an operation triggers a massive stress response—tissues get cut, immune cells flood the area, and the body’s inflammatory machinery kicks into overdrive. If a drug can dampen that response, it might help protect the heart and make it harder for infections to take hold. Dr. Tolan highlighted this in her interview, noting that “beyond their effects on appetite and satiety, these drugs may also modulate inflammatory pathways, which could help explain the associations we observed.” She added that it was especially striking to see the associations persist around the time of surgery, “when surgery typically triggers a substantial inflammatory response.” In other words, the very moment when the body is most inflamed is the moment when a GLP-1 drug might be most helpful.
But there is another side to the story that doctors have been wrestling with, and it involves the question of whether patients should keep taking these medications before going under anesthesia. The reason is that GLP-1 drugs slow down gastric emptying, meaning food and liquid stay in the stomach longer than usual. Even if a patient follows the standard rule of fasting for eight hours before surgery, there could still be residual stomach contents, which raises the risk of regurgitation and aspiration—inhaing stomach contents into the lungs—while the patient is sedated and unable to protect their airway. This is a genuine concern for anesthesiologists, and it has led to ongoing debate about whether patients should stop their GLP-1 medication for days or even weeks before an operation, or whether they should continue it right up to surgery. The new study doesn’t resolve that debate, but it adds an important layer of nuance. “Our findings do not eliminate that concern,” Dr. Tolan said, “but they do raise the possibility that continuing these medications could improve postoperative outcomes.” In other words, while there is a real risk related to anesthesia, there may also be real benefits related to recovery. Current guidance from U.S. medical societies generally favors an individualized approach, rather than telling every patient to stop their GLP-1 medication before surgery. The decision depends on the type of surgery, the patient’s underlying health, and how the drug is being used. But to make that decision truly evidence-based, doctors need to understand not just the risks but also the potential rewards.
Of course, this study is not the final word, and the researchers are careful not to overstate their conclusions. The biggest limitation is that it is an observational study, not a randomized controlled trial. That means it can show an association between GLP-1 use and better surgical outcomes, but it cannot prove that the drugs caused the improvement. It is possible, for example, that people who are prescribed GLP-1 medications simply have better access to healthcare, take their medications more consistently, or follow healthier lifestyles in ways that the statistical matching couldn’t fully capture. Dr. Jessica Duncan, a board-certified obesity medicine physician and chief medical officer at Ivím Health, pointed out in an interview with Newsweek that while the size and real-world scope of the study make the findings meaningful, the absolute differences between the two groups were relatively small. “For an individual patient, that may be a small benefit, but across the millions of surgeries performed each year, it could be clinically relevant,” she said. She also noted that the results are biologically plausible, because GLP-1 medications have already demonstrated cardiovascular benefits in randomized controlled trials and have anti-inflammatory effects. But she stressed that the observational design makes it impossible to establish cause and effect. The study also did not determine whether or when patients had stopped taking their GLP-1 medication before surgery, so it cannot tell us whether the protective effect came from having the drug active in the body during the operation or from the longer-term metabolic improvements it produces. And because the study focused only on inpatient surgeries and did not report aspiration outcomes, it “informs the potential benefit, but not the full risk picture,” Duncan said.
So what should patients and doctors actually do with this information? For now, the experts are clear: do not rush to start or stop a GLP-1 medication on your own before surgery. This study is not a reason to order a new prescription or to throw away that weekly injection ahead of an upcoming operation. If you are already taking a GLP-1 drug, the most important thing is to be transparent with your surgical and anesthesia teams. Tell them exactly which medication you take, what dose, and when you last took it. Let them make the call about whether to continue or pause the drug before surgery, because they are in the best position to weigh the anesthesia-related risks against the potential benefits. For doctors, the findings may encourage more thoughtful, individualized decisions about GLP-1 use in the perioperative period, rather than a blanket policy of withholding the medication from everyone. But the study doesn’t justify starting the drugs purely as a way to prevent surgical complications. As Dr. Duncan put it, “Ultimately, this study is reassuring and hypothesis-generating. The next step is prospective research that evaluates benefit and risk together, so we can define which patients benefit most and how these medications should be managed around surgery.” That kind of research could eventually lead to clearer protocols—maybe some patients continue their medication, maybe others pause it, and maybe certain high-risk groups gain the most from staying on it. Until then, the takeaway is hopeful but measured: these remarkable drugs may have even more hidden depths than we realized, but we need more proof before we can act on them with confidence.
